Editorial Article

Presenting the Journal of Oncological Studies

Dr. Mutian Zhang,

University of Nebraska Medical Center

USA

Oncology has reached its most current stage, which emphasizes precise and personalized treatments, in addition to accurate diagnosis and cancer prevention. As a result, clinicians and researchers are becoming increasingly specialized. Simultaneously, elucidation of information in each specialized field is exploding.
*Corresponding author:

Dr. Mutian Zhang

University of Nebraska Medical Center, USA

Oncology has reached its most current stage, which emphasizes precise and personalized treatments, in addition to accurate diagnosis and cancer prevention. As a result, clinicians and researchers are becoming increasingly specialized. Simultaneously, elucidation of information in each specialized field is exploding. There are, accordingly, countless scholarly journals that concentrate on the nuanced and specialized fields of oncological research and practice. Realizing that the ultimate goal of oncological study is patient care, I am very interested in knowing to what degree clinicians are concerned with progress in oncological studies (including outside their specific discipline), and if so, which journals are their best resources to provide high-quality multidisciplinary information. 

Consulted about the aforementioned questions, my radiation oncologist colleague, Dr. Vivek Verma, echoes, “I think this is important [knowing the progress in the other oncological fields], although knowing the progress in our field is much more important. If it's a practice-changing event in medical/surgical oncology, though, then it would be especially good to know. This is more applicable in some fields that are intrinsically more multidisciplinary, e.g., head & neck cancer.” For these purposes, our colleagues typically use the Journal of Clinical Oncology (JCO) as a go-to journal, with the New England Journal of Medicine (NEJM) as another possibility.

Indeed, JCO and NEJM are highly influential clinical journals, and one can find numerous excellent journals that, more or less, focus on some aspects of cancer research or treatment. Let us examine how the knowledge from different fields is put together – for instance, medical oncologist, surgeon, radiation oncologist, radiologist, pathologist, and other specialists are found in a standard tumor board. Modern cancer treatments are becoming increasingly personalized, and a greater emphasis on multidisciplinary thinking tends to make individual clinicians and researchers multidisciplinary as well. In order to treat non-small cell lung cancer patients using anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors [1], for example, the physician should be familiar with the fast evolving molecular diagnostic techniques, such as next-generation sequencing [2], to detect ALK gene disorder and the mutations causing treatment resistance. Thus, the physician will be able to choose new generation inhibitors that the pharmaceutical industry keeps developing. The same argument is applicable to investigators of cellular and molecular research. We envision that researchers and clinicians will be better served by a journal that reports oncological study results with the broadest spectrum. For this very reason, this new journal has been founded.
Greetings from the Journal of Oncological Studies! It is my sincere hope that JOS will become an invaluable platform for researchers and clinicians to exchange their findings and express their opinions. We wholeheartedly welcome established researchers as well as young investigators. Authors may find a variety of manuscript types with which to report interesting studies: full-length research paper, review article, mini-review, case report, opinion article, short communication, and letter to the editor. As the Journal grows, the latest research and clinical findings will rapidly disseminate, and thus the authors and readers of JOS will mutually benefit. We look forward to it!
Vivek Verma, MD, contributed to this Editorial.
1. Zhao Z, Verma V, Zhang M. Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biology & Therapy 2015; 16:1691-701.
2. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers 2015; 7:2023-36.

Published: 02 October 2016

Copyright: Copyright: © 2016 Mutian Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.